Trial reportCritical care (London, England)2018
Early application of continuous high-volume haemofiltration can reduce sepsis and improve the prognosis of patients with severe burns.
Trial report in Critical care (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Meta-Analysis of Renal Replacement Therapy for Burn Patients: Incidence Rate, Mortality, and Renal Outcome.Frontiers in medicine · 2021Pooled it
- Effect of High-Volume Hemofiltration in Critically Ill Patients: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Pooled it
- Continuous ultrafiltration during extracorporeal circulation and its effect on lactatemia: A randomized controlled trial.PloS one · 2020Trial
- Identification of diagnostic biomarkers and mitochondrial metabolic characteristics in sepsis-associated acute kidney injury.European journal of medical research · 2025Article
- Effluent-Dose Response of Continuous Haemofiltration Integrated into Veno-Venous ECMO for Septic Shock: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- [Expert consensus on the clinical treatment of burn patients complicated with Coronavirus infection (2023 version)].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Article
- Extracorporeal Blood Purification in Burns: For Whom, Why, and How?Blood purification · 2023Review
- Continuous Renal Replacement Therapy in Critically Ill Children.Turkish archives of pediatrics · 2022Article
- [Application effects of bundle nursing of citric acid extracorporeal anticoagulation on continuous renal replacement therapy of severe burn patients].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Article
- Regulatory T Cells: Angels or Demons in the Pathophysiology of Sepsis?Frontiers in immunology · 2022Review
- Insight Into Regulatory T Cells in Sepsis-Associated Encephalopathy.Frontiers in neurology · 2022Review
- Heparin-based blood purification attenuates organ injury in baboons withAmerican journal of physiology. Lung cellular and molecular physiology · 2021Article
- Blood purification for sepsis: an overview.Precision clinical medicine · 2021Review
- Application of Multifunctional Intelligent Suspension Treatment Beds in Nursing Care of Patients with Extensive Burns.Contrast media & molecular imaging · 2021Article
- Continuous Venovenous Hemofiltration is Associated with Improved Survival in Burn Patients with Shock: A Subset Analysis of a Multicenter Observational Study.Blood purification · 2021Observational
- lncRNA SNHG14 Plays a Role in Sepsis-Induced Acute Kidney Injury by Regulating miR-93.Mediators of inflammation · 2021Article
- Plasma Neutrophil-to-Lymphocyte Ratio on the Third Day Postburn is Associated with 90-Day Mortality Among Patients with Burns Over 30% of Total Body Surface Area in Two Chinese Burns Centers.Journal of inflammation research · 2021Article
- [Extracorporeal techniques for blood purification in sepsis: an update].Der Internist · 2020Review
- Burn injury.Nature reviews. Disease primers · 2020Review
- Hemofiltration in Patients with Severe Acute Pancreatitis (Review).Sovremennye tekhnologii v meditsine · 2020Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn the early stage of severe burn, patients often exhibit a high level of inflammatory mediators in blood and are likely to develop sepsis. High-volume haemofiltration (HVHF) can eliminate these inflammatory mediators. We hypothesised that early application of HVHF may be beneficial in reducing sepsis and improving the prognosis of patients with severe burns.
methodsAdults patients with burns ≥ 50% total burn surface area (TBSA) and in whom the sum of deep partial and full-thickness burn areas was ≥ 30% were enrolled in this randomised prospective study, and they were divided into control (41 cases) and HVHF (41 cases) groups. Patients in the control group received standard management for major burns, whereas the HVHF group additionally received HVHF treatment (65 ml/kg/h for 3 consecutive days) within 3 days after burn. The incidence of sepsis and mortality, some laboratory data, levels of inflammatory cytokines in the blood, HLA-DR expression on CD14
resultsThe incidence of sepsis, septic shock and duration of vasopressor treatment were decreased significantly in the HVHF group. In addition, in the subgroup of patients with burns ≥ 80% TBSA, the 90-day mortality showed significant decreases in the HVHF group. The ratio of arterial oxygen partial pressure to the fraction of inspiration oxygen was improved after HVHF treatment. In the patients who received HVHF treatment, the blood levels of inflammatory cytokines, including tumour necrosis factor-α, interleukin (IL)-1β, IL-6 and IL-8, as well as the blood level of procalcitonin were found to be lower than in the control group. Moreover, higher HLA-DR expression on CD14
conclusionsEarly application of HVHF benefits patients with severe burns, especially for those with a greater burn area (≥ 80% TBSA), decreasing the incidence of sepsis and mortality. This effect may be attributed to its early clearance of inflammatory mediators and the recovery of the patient's immune status.
trial registrationChinese Clinical Trial Register, ChiCTR-TRC-12002616 . Registered on 24 October 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.